Apellis Pharmaceuticals (APLS)

APLS was delisted on the 13th of May, 2026.

• Market cap: $5.25B
• Sector: Healthcare
• Industry: Biotechnology

About: Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).

Employees: 733